Drugs / ATRELEUTON
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00552188 | Oct 2007 → Oct 2009 | acute coronary syndrome | Tallikut Pharmaceuticals, Inc. | Completed | Missed primary |
| Phase 2 | NCT00358826 | Jul 2006 → Aug 2008 | coronary atherosclerosis | Tallikut Pharmaceuticals, Inc. | Completed | Met primary |
| Phase 2 | NCT00352417 | Jul 2006 → Jul 2008 | atherosclerosis | Tallikut Pharmaceuticals, Inc. | Completed | Missed primary |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATRELEUTON | ChEMBL registry synonym — accepted as the source's own label CHEMBL59356 ↗ |
| Known as | A-85761 | ChEMBL registry synonym — accepted as the source's own label CHEMBL59356 ↗ |
| Known as | A-85761.0 | ChEMBL registry synonym — accepted as the source's own label CHEMBL59356 ↗ |
| Known as | ABBOTT-85761 | ChEMBL registry synonym — accepted as the source's own label CHEMBL59356 ↗ |
| Known as | ABT-761 | ChEMBL registry synonym — accepted as the source's own label CHEMBL59356 ↗ |
| Known as | VIA-2291 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00552188 ↗ |
| Action | Inhibit | “Arachidonate 5-lipoxygenase inhibitor” CHEMBL59356 ↗1“a 5-Lipoxygenase Inhibitor” NCT00352417 ↗ |
| Modality | Small molecule | — CHEMBL59356 ↗ |
| Route | Oral | “100 mg, oral dosing, 1 time daily for 12 weeks” NCT00352417 ↗ |
| Target | ALOX5 | “Arachidonate 5-lipoxygenase inhibitor” CHEMBL59356 ↗ |